Yazar "Kansu, Aydan" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • [ X ]
    Öğe
    Growth, tolerance and safety outcomes with use of an extensively hydrolyzed casein-based formula in infants with cow's milk protein allergy
    (Frontiers Media Sa, 2023) Kansu, Aydan; Urganci, Nafiye; Bukulmez, Aysegul; Kutluk, Gunsel; Taskin, Didem Gulcu; Keskin, Lutfiye Sahin; Igde, Mahir
    ObjectiveTo evaluate growth, tolerance and safety outcomes with use of an extensively hydrolyzed casein-based formula (eHCF) in infants with cow's milk protein allergy (CMPA). MethodsA total of 226 infants (mean & PLUSMN; SD age: 106.5 & PLUSMN; 39.5 days, 52.7% were girls) with CMPA who received eHCF comprising at least half of the daily dietary intake were included. Data on anthropometrics [weight for age (WFA), length for age (LFA) and weight for length (WFL) z-scores] were recorded at baseline (visit 1), while data on infant feeding and stool records, anthropometrics and Infant Feeding and Stool Patterns and Formula Satisfaction Questionnaires were recorded at visit 2 (on Days 15 & PLUSMN; 5) and visit 3 (on Days 30 & PLUSMN; 5). ResultsFrom baseline to visit 2 and visit 3, WFA z-scores (from -0.60 & PLUSMN; 1.13 to -0.54 & PLUSMN; 1.09 at visit 2, and to -0.44 & PLUSMN; 1.05 at visit 3, p < 0.001) and WFL z-scores (from -0.80 & PLUSMN; 1.30 to -0.71 & PLUSMN; 1.22 at visit 2, and to -0.64 & PLUSMN; 1.13 at visit 3, p = 0.002) were significantly increased. At least half of infants never experienced irritability or feeding refusal (55.7%) and spit-up after feeding (50.2%). The majority of mothers were satisfied with the study formula (93.2%), and wished to continue using it (92.2%). ConclusionsIn conclusion, eHCF was well-accepted and tolerated by an intended use population of infants & LE; 6 months of age with CMPA and enabled adequate volume consumption and improved growth indices within 30 days of utilization alongside a favorable gastrointestinal tolerance and a high level of parental satisfaction.
  • [ X ]
    Öğe
    Growth, tolerance and safety outcomes with use of an extensively hydrolyzed casein-based formula in infants with cow’s milk protein allergy
    (Frontiers Media SA, 2023) Kansu, Aydan; Urganci, Nafiye; Bukulmez, Aysegul; Kutluk, Gunsel; Gulcu Taskin, Didem; Sahin Keskin, Lutfiye; Igde, Mahir
    Objective: To evaluate growth, tolerance and safety outcomes with use of an extensively hydrolyzed casein-based formula (eHCF) in infants with cow’s milk protein allergy (CMPA). Methods: A total of 226 infants (mean ± SD age: 106.5 ± 39.5 days, 52.7% were girls) with CMPA who received eHCF comprising at least half of the daily dietary intake were included. Data on anthropometrics [weight for age (WFA), length for age (LFA) and weight for length (WFL) z-scores] were recorded at baseline (visit 1), while data on infant feeding and stool records, anthropometrics and Infant Feeding and Stool Patterns and Formula Satisfaction Questionnaires were recorded at visit 2 (on Days 15 ± 5) and visit 3 (on Days 30 ± 5). Results: From baseline to visit 2 and visit 3, WFA z-scores (from ?0.60 ± 1.13 to ?0.54 ± 1.09 at visit 2, and to ?0.44 ± 1.05 at visit 3, p < 0.001) and WFL z-scores (from ?0.80 ± 1.30 to ?0.71 ± 1.22 at visit 2, and to ?0.64 ± 1.13 at visit 3, p = 0.002) were significantly increased. At least half of infants never experienced irritability or feeding refusal (55.7%) and spit-up after feeding (50.2%). The majority of mothers were satisfied with the study formula (93.2%), and wished to continue using it (92.2%). Conclusions: In conclusion, eHCF was well-accepted and tolerated by an intended use population of infants ? 6 months of age with CMPA and enabled adequate volume consumption and improved growth indices within 30 days of utilization alongside a favorable gastrointestinal tolerance and a high level of parental satisfaction. 2023 Kansu, Urganci, Bukulmez, Kutluk, Gulcu Taskin, Sahin Keskin, Igde, Molon, Dogan, Sekerel, Yuksek, Bostanci, Gerenli, Polat, Dalgic, Ayyildiz, Usta, Basturk, Yuce Kirmemis, Tuna Kirsaclioglu, Gulerman, Alptekin Sarioglu and Erdogan.
  • Küçük Resim
    Öğe
    Human tissue transglutaminase antibody screening by immunochromatographic line immunoassay for early diagnosis of celiac disease in Turkish children
    (2008) Demirçeken, Fulya G.; Kansu, Aydan; Kuloğlu, Zarife; Girgin, Nurten; Güriz, Haluk; Ensari, Arzu
    Amaç: Çölyak hastalığı tüm dünyada yaygın sıklıkta görülmektedir. Türkiye?de dünya ile karşılaştırılabilecek epidemiyolojik veriler sınırlı sayıdadır. Bu ön hazırlayıcı çalışmanın amacı, Türk çocuklarında çölyak hastalığı sıklığını 1000 olguda yeni, kolay ve görsel tek adımda yapılabilen bir immünolojik tarama yöntemiyle belirlemektir. Yöntem: Bu prospektif çalı şma, Ankara Üniversitesi Tıp Fakültesi Çocuk Polikliniğine başvuran, sağlıklı görünen veya çölyak hastalığı dışında bir rahatsı zlığı olan, 2-18 yaş arası 1000 çocuk ve ergenden bilgilendirilmiş onam formu ile gönüllü olarak alınan serum örneklerinde yapıldı. Serumlar insan doku transglutaminazına ve gliadine karşı oluşmuş IgA sınıfı antikorlar için hızlı, görsel immünokromatografik çölyak hastalığı çizgisel immun yöntemiyle çalışıldı. Tarama testi sonuçları pozitif olan serumlar ikinci basamak doğrulama aşaması için ELISA yöntemi ile insan doku transglutaminazına karşı oluşmuş endomisyal antikor IgA ve antigliadin antikorlar IgA/IgG için ayrıca test edildiler. Anti doku transglutaminaz ve/veya endomisyal antikor pozitif olan bütün çocuklara ince barsak biyopsisi önerildi. Bulgular: 1000 olgunun 10?unda (%1) insan doku transglutaminazına karşı pozitif antikor tarama sonucu saptandı. Bütün doku transglutaminaz antikoru pozitif örnekler ELISA yöntemiyle endomisyal antikor çalışıldığında uyumlu görüldüler. Takiben yapılan ince barsak biyopsisinde de biri hariç dokuz olguda çölyak hastalığı tanısı doğrulandı. Biyopsi ile kanıtlanmış çölyak hastalığı prevalansı 1/111 (%0,9) olarak saptandı. Sonuçlar: Çölyak hastalığı için anti-doku transglutaminaz antikorlarının kolay görsel bir yöntemle belirlenmesi ELISA yöntemi kadar güvenilirdir. Yapması ve yorumlaması kolay bu testin, ucuz ve hızlı bir tarama yöntemi olarak geniş toplum tabanlı çalışmalarda uygulanabileceği düşünüldü. Bu ön çalışmada Türk çocukları örnek grubunda saptanan çölyak hastalığı sıklığı (1:111 veya %0.9) Avrupa, Orta Doğu ülkeleri ve ABD verileri ile benzer bulundu.
  • [ X ]
    Öğe
    The Frequency of Lysosomal Acid Lipase Deficiency in Children With Unexplained Liver Disease
    (Lippincott Williams & Wilkins, 2019) Kuloglu, Zarife; Kansu, Aydan; Selbuz, Suna; Kalayci, Ayhan G.; Sahin, Gulseren; Kirsaclioglu, Ceyda Tuna; Demiroren, Kaan
    Objectives: Evidence suggests that lysosomal acid lipase deficiency (LAL-D) is often underdiagnosed because symptoms may be nonspecific. We aimed to investigate the prevalence of LAL-D in children with unexplained liver disease and to identify demographic and clinical features with a prospective, multicenter, cross-sectional study. Methods: Patients (aged 3 months-18 years) who had unexplained transaminase elevation, unexplained hepatomegaly or hepatosplenomegaly, obesity-unrelated liver steatosis, biopsy-proven cryptogenic fibrosis and cirrhosis, or liver transplantation for cryptogenic cirrhosis were enrolled. A Web-based electronic data collection system was used. LAL activity (nmol/punch/h) was measured using the dried blood spot method and classified as LAL-D(<0.02), intermediate (0.02-0.37) or normal (>0.37). Asecond dried blood spot sample was obtained from patients with intermediate LAL activity for confirmation of the result. Results: A total of 810 children (median age 5.6 years) from 795 families were enrolled. The reasons for enrollment were unexplained transaminase elevation (62%), unexplained organomegaly (45%), obesity-unrelated liver steatosis (26%), cryptogenic fibrosis and cirrhosis (6%), and liver transplantation for cryptogenic cirrhosis (<1%). LAL activity was normal in 634 (78%) and intermediate in 174 (21%) patients. LAL-D was identified in 2 siblings aged 15 and 6 years born to unrelated parents. Dyslipidemia, liver steatosis, and mild increase in aminotransferases were common features in these patients. Moreover, the 15-year-old patient showed growth failure and microvesicular steatosis, portal inflammation, and bridging fibrosis in the liver biopsy. Based on 795 families, 2 siblings in the same family were identified as LAL-D cases, making the prevalence of LAL-D in this study population, 0.1% (0.125%-0.606%). In the repeated measurement (76/174), LAL activity remained at the intermediate level in 38 patients. Conclusions: Overall, the frequency of LAL-D patients in this study (0.1%) suggests that LAL-D seems to be rare even in the selected high-risk population.